Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes.

Bao-Ngoc Nguyen,Shweta Mital,Shawn Bugden,Hai V Nguyen

Diabetes, obesity & metabolism（2023）

引用 1|浏览6

暂无评分

摘要

Dapagliflozin + SoC was not cost-effective versus canagliflozin + SoC in patients with CKD and T2D over the lifetime horizon. However, adding canagliflozin or dapagliflozin to SoC was less costly and more effective relative to SoC alone for treatment of CKD and T2D.

查看译文

关键词

dapagliflozin,canagliflozin,chronic kidney disease,diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要